Amisulpride in Schizophrenic Acute Phase Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To collect the safety and response of using Amisulpride in acute schizophrenic patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Amisulpride; Sulpiride; Sultopride

Criteria

Inclusion Criteria:

• Patient diagnosed as Diagnostic and Statistical Manual of Mental Disorder, 4th edition, as paranoid, disorganized or undifferentiated type of schizophrenia in acute episode

Exclusion Criteria:

• Patients previously treated with amisulpride

• Patients have comorbidity which may interfere with the treatment or follow-up

• Patients currently taking depot antipsychotics (at least 30 days washout period is needed)

• Patients currently/ or recently (< 3 months) withdrawn from drug or alcohol abuse

• Pregnant or lactation

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.